RecruitingEarly Phase 1NCT06238908
Safety and Efficacy Study of NGGT003 in Hemophilia A Patients
Studying Hemophilia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Principal Investigator
- Lei Zhang, MDInstitute of Hematology & Blood Diseases Hospital, China
- Intervention
- NGGT003(drug)
- Enrollment
- 6 enrolled
- Eligibility
- 18 years · MALE
- Timeline
- 2024 – 2030
Study locations (1)
- Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06238908 on ClinicalTrials.govOther trials for Hemophilia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07416604A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia AHoffmann-La Roche
- RECRUITINGPHASE3NCT07545395Safety of KN057 Prophylaxis in Patients With Haemophilia A or BSuzhou Alphamab Co., Ltd.
- RECRUITINGPHASE4NCT07406139PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE3NCT04563520SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisEmory University
- RECRUITINGNCT06992076Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience RegistryInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNCT07101926Monitoring of Anti-TFPI in HemophiliaHospices Civils de Lyon
- RECRUITINGPHASE4NCT06941870Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial HypertrophySanofi
- RECRUITINGNCT07314983Long-term Anticoagulation in a Patient With Severe Hemophilia AUniversity Hospital, Strasbourg, France